Sports Medicine

Sports medicine was the birthplace of clinical PRP — and the evidence base for tendinopathies has now matured to the point where a clear temporal pattern emerges across multiple meta-analyses: corticosteroids provide superior short-term relief (under 2 months), but PRP overtakes them at 6 months and maintains superiority through 12 months.

For lateral epicondylitis, Xu et al. (2024) found PRP provides significantly better long-term VAS scores (MD -2.18, P < 0.0001) and DASH scores (MD -8.13, P < 0.0001) versus corticosteroids at 6 or more months. For plantar fasciitis, Zuo et al. (2025) analyzed 24 RCTs (1,653 participants) and confirmed PRP significantly outperforms corticosteroids at both 3 and 6 months on VAS and AOFAS scores, with additional reduction in fascia thickness. For Achilles tendinopathy, Ahmed et al. (2025) pooled 13 studies showing 72% patient satisfaction with leukocyte-poor PRP preferred.

The protein enrichment dimension adds a layer standard PRP cannot access. Concentrated fibronectin mediates tenocyte adhesion and migration — critical for tendon healing where the extracellular matrix must be rebuilt. Concentrated A2M inhibits the MMP cascade that perpetuates chronic tendinopathy. The fibrin scaffold provides sustained growth factor delivery over days rather than the bolus release of direct injection.

autologIX’s higher output volume (6–7 mL) is designed for applications where tendon coverage or multiple injection sites benefit from greater volume — such as extensive lateral epicondyle debridement or multi-level plantar fascia fenestration.

Clinical studies investigating autologIX outcomes for sports medicine are in development.